First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
Barbara Eichhorst(University of Cologne), Anna‐Maria Fink(University of Cologne), Jasmin Bahlo(University of Cologne), Raymonde Busch, Gábor Kovács(University of Cologne), Christian Maurer(University of Cologne), Elisabeth Lange(Evangelisches Krankenhaus Hamm), H. Köppler(Koblenz University of Applied Sciences), Michael Kiehl(Klinikum Frankfurt Höchst), Martin Sökler(University Children's Hospital Tübingen), Rudolf Schlag(Universitätsklinikum Würzburg), Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), Georg Köchling(Nephrologisches Zentrum Villingen-Schwenningen), Christoph Plöger(University of Mannheim), Michael Gregor(Luzerner Kantonsspital), Torben Plesner(Vejle Sygehus), Marek Trněný(Charles University), Kirsten Fischer(University of Cologne), Harmut Döhner(Universität Ulm), Michael Kneba(University Hospital Schleswig-Holstein), Clemens‐Martin Wendtner(München Klinik Schwabing), Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Karl‐Anton Kreuzer(University of Cologne), Stephan Stilgenbauer(Universität Ulm), Sebastian Böttcher(University Hospital Schleswig-Holstein), Michael Hallek(University of Cologne)
Cited by 621
Abstract
Related Papers
No related papers found
Powered by citation graph analysis